JP2025513786A - 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出 - Google Patents

無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出 Download PDF

Info

Publication number
JP2025513786A
JP2025513786A JP2024559196A JP2024559196A JP2025513786A JP 2025513786 A JP2025513786 A JP 2025513786A JP 2024559196 A JP2024559196 A JP 2024559196A JP 2024559196 A JP2024559196 A JP 2024559196A JP 2025513786 A JP2025513786 A JP 2025513786A
Authority
JP
Japan
Prior art keywords
cancer
regions
training
computing system
additional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513786A5 (https=
Inventor
ユペン ヘ，
ジャオレン ヘ，
アリエル ジャイモビッチ，
グリーンウォルド， ウィリアム ウォルター ヤング
ウィリアム ジェイ． グリーンリーフ，
サイ チェン，
ティンティン ジアン，
ジュン ジャオ，
Original Assignee
ガーダント ヘルス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ガーダント ヘルス， インコーポレイテッド filed Critical ガーダント ヘルス， インコーポレイテッド
Publication of JP2025513786A publication Critical patent/JP2025513786A/ja
Publication of JP2025513786A5 publication Critical patent/JP2025513786A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Databases & Information Systems (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Software Systems (AREA)
  • Surgery (AREA)
  • Evolutionary Computation (AREA)
  • Oncology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
JP2024559196A 2022-04-07 2023-04-07 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出 Pending JP2025513786A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263328602P 2022-04-07 2022-04-07
US63/328,602 2022-04-07
US202263336852P 2022-04-29 2022-04-29
US63/336,852 2022-04-29
PCT/US2023/065560 WO2023197004A1 (en) 2022-04-07 2023-04-07 Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules

Publications (2)

Publication Number Publication Date
JP2025513786A true JP2025513786A (ja) 2025-04-30
JP2025513786A5 JP2025513786A5 (https=) 2026-04-07

Family

ID=86328669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559196A Pending JP2025513786A (ja) 2022-04-07 2023-04-07 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出

Country Status (5)

Country Link
US (1) US20250273295A1 (https=)
EP (1) EP4504971A1 (https=)
JP (1) JP2025513786A (https=)
CA (1) CA3246524A1 (https=)
WO (1) WO2023197004A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115457361A (zh) * 2022-09-19 2022-12-09 京东方科技集团股份有限公司 分类模型获取方法、表达类别确定方法、装置、设备及介质
US20250125050A1 (en) * 2023-10-13 2025-04-17 Tempus Ai, Inc. Systems and methods for molecular residual disease liquid biopsy assay
GB202317261D0 (en) * 2023-11-10 2023-12-27 Cancer Research Tech Ltd Methods for determining cancers
WO2025106275A1 (en) * 2023-11-15 2025-05-22 Guardant Health, Inc. Minimum residual disease (mrd) detection in early stage cancer using urine
WO2025155784A1 (en) * 2024-01-18 2025-07-24 Grail, Inc. Systems and methods to identify clonal hematopoiesis related methylation signatures
WO2026076332A1 (en) * 2024-10-03 2026-04-09 Guardant Health, Inc. Methods involving multi-modal tumor variant identification and tracking of tumor molecules

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US20030017081A1 (en) 1994-02-10 2003-01-23 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
WO2003046146A2 (en) 2001-11-28 2003-06-05 Applera Corporation Compositions and methods of selective nucleic acid isolation
ATE443765T1 (de) 2003-03-21 2009-10-15 Santaris Pharma As Analoga kurzer interferierender rna (sirna)
US20110028333A1 (en) * 2009-05-01 2011-02-03 Brown University Diagnosing, prognosing, and early detection of cancers by dna methylation profiling
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
GB2559073A (en) 2012-06-08 2018-07-25 Pacific Biosciences California Inc Modified base detection with nanopore sequencing
CN104781421B (zh) 2012-09-04 2020-06-05 夸登特健康公司 检测稀有突变和拷贝数变异的系统和方法
EP4358097A1 (en) 2014-07-25 2024-04-24 University of Washington Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
WO2018009723A1 (en) 2016-07-06 2018-01-11 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
US9850523B1 (en) 2016-09-30 2017-12-26 Guardant Health, Inc. Methods for multi-resolution analysis of cell-free nucleic acids
MX2019007444A (es) 2016-12-22 2019-08-16 Guardant Health Inc Metodos y sistemas para analisis de moleculas de acido nucleico.
WO2020160414A1 (en) 2019-01-31 2020-08-06 Guardant Health, Inc. Compositions and methods for isolating cell-free dna
ES2994567T3 (en) * 2019-02-05 2025-01-27 Grail Inc Detecting cancer, cancer tissue of origin, and/or a cancer cell type
US20210407623A1 (en) * 2020-03-31 2021-12-30 Guardant Health, Inc. Determining tumor fraction for a sample based on methyl binding domain calibration data
EP4153771A4 (en) 2020-05-19 2024-07-24 The Trustees of the University of Pennsylvania COMPOSITIONS AND METHODS FOR CARBOXYMETHYLATION OF DNA CYTOSINE
CA3225385A1 (en) 2021-07-12 2023-01-19 The Trustees Of The University Of Pennsylvania Modified adapters for enzymatic dna deamination and methods of use thereof for epigenetic sequencing of free and immobilized dna

Also Published As

Publication number Publication date
EP4504971A1 (en) 2025-02-12
US20250273295A1 (en) 2025-08-28
WO2023197004A1 (en) 2023-10-12
CA3246524A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JP7573536B2 (ja) 無細胞ｄｎａを単離するための組成物および方法
JP7717057B2 (ja) メチル化分配アッセイにおいて無細胞ｄｎａを解析するための組成物および方法
JP2025513786A (ja) 無細胞核酸分子のメチル化状態に基づいた腫瘍の存在の検出
US20220344004A1 (en) Detecting the presence of a tumor based on off-target polynucleotide sequencing data
JP2024513668A (ja) 分子応答を分析するための方法および関連する態様
JP2023551292A (ja) メチル化されたポリヌクレオチドを富化するための組成物および方法
US20250078955A1 (en) Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
US20250101494A1 (en) Methods for analyzing cytosine methylation and hydroxymethylation
EP4453241A1 (en) Methods and systems for combinatorial chromatin-ip sequencing
US20260120878A1 (en) Methods for early detection of cancer
JP2025522763A (ja) 異常にメチル化されたｄｎａの富化
JP2024523401A (ja) コピー数情報に基づく組織起源分析のための方法および組成物
JP2023524681A (ja) 分配された核酸を使用した配列決定のための方法
WO2022204730A1 (en) Methods and compositions for quantifying immune cell dna
CN118974279A (zh) 基于无细胞核酸分子的甲基化状态检测肿瘤的存在
WO2026090570A1 (en) Detecting the presence of a biological condition based on a nucleic acid sample data analysis
WO2025064706A1 (en) Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
WO2025208044A1 (en) Methods for cancer detection using molecular patterns
WO2025076452A1 (en) Detecting tumor-related information based on methylation status of cell-free nucleic acid molecules
WO2026073140A1 (en) Framework to identify genomic regions indicative of one or more biological conditions
US20240412815A1 (en) Detecting homologous recombination deficiences based on methylation status of cell-free nucleic acid molecules
WO2025250656A1 (en) Machine learning classification model for cancer detection
US20250388972A1 (en) Compositions and methods for detection of metastasis
Filges Next generation molecular diagnostics using ultrasensitive sequencing
WO2025235602A1 (en) Predictive, prognostic signatures for immuno-oncology using liquid biopsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260330